BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34271911)

  • 21. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy.
    Willner J; Jost A; Baier K; Flentje M
    Strahlenther Onkol; 2003 Aug; 179(8):548-56. PubMed ID: 14509954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapeutic efficacy of three-dimensional conformal radiation therapy for patients with locally advanced non-small cell lung cancer].
    Cao JZ; Ou GF; Liang J; Lü JM; Zhou ZM; Chen DF; Xiao ZF; Feng QF; Zhang HX; Wang LH; Yin WB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):529-34. PubMed ID: 22093633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.
    Fleckenstein J; Kremp K; Kremp S; Palm J; Rübe C
    Strahlenther Onkol; 2016 Feb; 192(2):75-82. PubMed ID: 26438071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and dosimetric factors of radiation-induced esophageal injury: radiation-induced esophageal toxicity.
    Qiao WB; Zhao YH; Zhao YB; Wang RZ
    World J Gastroenterol; 2005 May; 11(17):2626-9. PubMed ID: 15849822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between DVH parameters and lung function changes before and after radiotherapy and the occurrence of radiation induced lung injury (RILI).
    Sha S; Dong J; Wang M; Chen Z; Gao P
    Neuro Endocrinol Lett; 2021 Sep; 42(5):297-304. PubMed ID: 34506093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of three-dimensional radiation on the treatment of non-small cell lung cancer.
    Armstrong J; McGibney C
    Radiother Oncol; 2000 Aug; 56(2):157-67. PubMed ID: 10927134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
    Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment planning comparison between conformal radiotherapy and helical tomotherapy in the case of locally advanced-stage NSCLC.
    Cattaneo GM; Dell'oca I; Broggi S; Fiorino C; Perna L; Pasetti M; Sangalli G; di Muzio N; Fazio F; Calandrino R
    Radiother Oncol; 2008 Sep; 88(3):310-8. PubMed ID: 18692266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy.
    Chen J; Lu JJ; Ma N; Zhao J; Chen C; Fan M; Jiang G; Mao J
    Radiat Oncol; 2019 Jan; 14(1):16. PubMed ID: 30683133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.
    Bradley JD; Ieumwananonthachai N; Purdy JA; Wasserman TH; Lockett MA; Graham MV; Perez CA
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):49-57. PubMed ID: 11777621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of dose distribution in the 'Rind'--a volume outside the PTV--in 3-dimensional conformal radiation therapy of non-small cell lung cancer.
    McGibney C; Holmberg O; McClean B; Armstrong J
    Radiother Oncol; 2003 Jan; 66(1):87-93. PubMed ID: 12559525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer.
    Murshed H; Liu HH; Liao Z; Barker JL; Wang X; Tucker SL; Chandra A; Guerrero T; Stevens C; Chang JY; Jeter M; Cox JD; Komaki R; Mohan R
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1258-67. PubMed ID: 15001271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric factors and Lyman normal-tissue complication modelling analysis for predicting radiation-induced lung injury in postoperative breast cancer radiotherapy: a prospective study.
    Zhou ZR; Han Q; Liang SX; He XD; Cao NY; Zi YJ
    Oncotarget; 2017 May; 8(20):33855-33863. PubMed ID: 27806340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potential to reduce pulmonary toxicity: the use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer.
    Lavrenkov K; Christian JA; Partridge M; Niotsikou E; Cook G; Parker M; Bedford JL; Brada M
    Radiother Oncol; 2007 May; 83(2):156-62. PubMed ID: 17493699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose escalation of chart in non-small cell lung cancer: is three-dimensional conformal radiation therapy really necessary?
    McGibney C; Holmberg O; McClean B; Williams C; McCrea P; Sutton P; Armstrong J
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):339-50. PubMed ID: 10487554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.